Cutaneous reactions post‐COVID‐19 vaccination. Case series and literature review
Abstract Background In Saudi Arabia, three approved vaccines against severe acute respiratory syndrome coronavirus 2 (AstraZeneca [AZD1222], Pfizer‐BioNTech [BNT162b2] and [Ad26. COV 2‐S] Moderna vaccine) have been administered to the population. Objective To characterise cutaneous adverse events as...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-12-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.56 |
| _version_ | 1828098014855561216 |
|---|---|
| author | Fatimah J. Al‐Muqarrab Omar M. Alakloby Mohammed A. Al Ameer Abdulmohsen M. Alhajri |
| author_facet | Fatimah J. Al‐Muqarrab Omar M. Alakloby Mohammed A. Al Ameer Abdulmohsen M. Alhajri |
| author_sort | Fatimah J. Al‐Muqarrab |
| collection | DOAJ |
| description | Abstract Background In Saudi Arabia, three approved vaccines against severe acute respiratory syndrome coronavirus 2 (AstraZeneca [AZD1222], Pfizer‐BioNTech [BNT162b2] and [Ad26. COV 2‐S] Moderna vaccine) have been administered to the population. Objective To characterise cutaneous adverse events associated with COVID‐19 vaccines. Methodology We collected information on 26 patients presented to two secondary health care facilities, over the period extending from mid of December 2020 to the 1st of January 2022 with cutaneous reactions after COVID‐19 vaccine administration. Data were descriptively analysed using Statistical Package for the Social Sciences, SPSS 23rd version. Results A total of 53.8% of the patients were male; 31% of the patients reported having at least one chronic illness. Reactions were most frequent after the first dose (57.6% of the patients). Messenger RNA‐based vaccines were the most frequently noted vaccines associated with the reactions (76.9% of the cases). The most common reactions were cutaneous small‐vessel vasculitis (19.2%), interface/lichenoid reactions (19.2%), psoriasis (15.4%), and acute urticaria (11.5%). Only 11.5% patients required admission to the hospital for their clinical presentation. Conclusion Most of our patients had mild reactions and were successfully managed with supportive treatments. However, still some patients may experience severe or long‐lasting reactions requiring systemic therapies. |
| first_indexed | 2024-04-11T07:55:51Z |
| format | Article |
| id | doaj.art-7066a1a01ae3434aa2206fae0f45ef69 |
| institution | Directory Open Access Journal |
| issn | 2768-6566 |
| language | English |
| last_indexed | 2024-04-11T07:55:51Z |
| publishDate | 2022-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj.art-7066a1a01ae3434aa2206fae0f45ef692022-12-22T04:35:57ZengWileyJEADV Clinical Practice2768-65662022-12-011439139610.1002/jvc2.56Cutaneous reactions post‐COVID‐19 vaccination. Case series and literature reviewFatimah J. Al‐Muqarrab0Omar M. Alakloby1Mohammed A. Al Ameer2Abdulmohsen M. Alhajri3Dermatology Department King Fahd Hospital Hofuf Saudi ArabiaDepartment of Dermatology Imam Abdulrahman Bin Faisal University (formerly University of Dammam) Dammam Saudi ArabiaDermatology Department King Fahd Hospital Hofuf Saudi ArabiaDermatology Department King Fahd Hospital Hofuf Saudi ArabiaAbstract Background In Saudi Arabia, three approved vaccines against severe acute respiratory syndrome coronavirus 2 (AstraZeneca [AZD1222], Pfizer‐BioNTech [BNT162b2] and [Ad26. COV 2‐S] Moderna vaccine) have been administered to the population. Objective To characterise cutaneous adverse events associated with COVID‐19 vaccines. Methodology We collected information on 26 patients presented to two secondary health care facilities, over the period extending from mid of December 2020 to the 1st of January 2022 with cutaneous reactions after COVID‐19 vaccine administration. Data were descriptively analysed using Statistical Package for the Social Sciences, SPSS 23rd version. Results A total of 53.8% of the patients were male; 31% of the patients reported having at least one chronic illness. Reactions were most frequent after the first dose (57.6% of the patients). Messenger RNA‐based vaccines were the most frequently noted vaccines associated with the reactions (76.9% of the cases). The most common reactions were cutaneous small‐vessel vasculitis (19.2%), interface/lichenoid reactions (19.2%), psoriasis (15.4%), and acute urticaria (11.5%). Only 11.5% patients required admission to the hospital for their clinical presentation. Conclusion Most of our patients had mild reactions and were successfully managed with supportive treatments. However, still some patients may experience severe or long‐lasting reactions requiring systemic therapies.https://doi.org/10.1002/jvc2.56adenovirus vaccinecoronavirus vaccineCOVID‐19 vaccinecutaneous reactionsmRNA vaccineside effects |
| spellingShingle | Fatimah J. Al‐Muqarrab Omar M. Alakloby Mohammed A. Al Ameer Abdulmohsen M. Alhajri Cutaneous reactions post‐COVID‐19 vaccination. Case series and literature review JEADV Clinical Practice adenovirus vaccine coronavirus vaccine COVID‐19 vaccine cutaneous reactions mRNA vaccine side effects |
| title | Cutaneous reactions post‐COVID‐19 vaccination. Case series and literature review |
| title_full | Cutaneous reactions post‐COVID‐19 vaccination. Case series and literature review |
| title_fullStr | Cutaneous reactions post‐COVID‐19 vaccination. Case series and literature review |
| title_full_unstemmed | Cutaneous reactions post‐COVID‐19 vaccination. Case series and literature review |
| title_short | Cutaneous reactions post‐COVID‐19 vaccination. Case series and literature review |
| title_sort | cutaneous reactions post covid 19 vaccination case series and literature review |
| topic | adenovirus vaccine coronavirus vaccine COVID‐19 vaccine cutaneous reactions mRNA vaccine side effects |
| url | https://doi.org/10.1002/jvc2.56 |
| work_keys_str_mv | AT fatimahjalmuqarrab cutaneousreactionspostcovid19vaccinationcaseseriesandliteraturereview AT omarmalakloby cutaneousreactionspostcovid19vaccinationcaseseriesandliteraturereview AT mohammedaalameer cutaneousreactionspostcovid19vaccinationcaseseriesandliteraturereview AT abdulmohsenmalhajri cutaneousreactionspostcovid19vaccinationcaseseriesandliteraturereview |